Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
population currently takes GLP-1 medications , yet most discontinue within a year
The primary endpoint was percentage change from baseline in UACR at week 24
Inadequate dosing may occur when patients remain on subtherapeutic doses due to side effect concerns or insurance coverage limitations
Only one Phase I clinical trial has been registered, and no Phase 2 or 3 trials have been completed
Medications that carry elevated hypoglycemia risk when combined with retatrutide include insulin (all types), sulfonylureas like glipizide, glyburide, and glimepiride, and meglitinides like repaglinide and nateglinide
US$ 25.93
US$ 21.43
US$ 23.26
US$ 23.85
